Evolutionary development in the human populations immune to Plasmodium vivax due to the presence of a mutated enhancer for the glycoprotein present on their red blood corpuscles (RBCs). Introduction: A protist named P. vivax is mainly responsible for causing malaria. It gets attached to the RBCs after entering the blood. It has been found that some human populations in Africa are immune to P. vivax due to the absence of this particular glycoprotein on their RBCs. The transcription of this glycoprotein is influenced by the enhancers in a variety of tissues. In individuals immune to this form of malaria, the enhancer that is normally expressed in RBC precursors is mutated.

Question

Want to see the full answer?

Answer 1

Question

Chapter 19.4, Problem 3R

Summary Introduction

To review:

Evolutionary development in the human populations immune to Plasmodium vivax due to the presence of a mutated enhancer for the glycoprotein present on their red blood corpuscles (RBCs).

Introduction:

A protist named P. vivax is mainly responsible for causing malaria. It gets attached to the RBCs after entering the blood. It has been found that some human populations in Africa are immune to P. vivax due to the absence of this particular glycoprotein on their RBCs. The transcription of this glycoprotein is influenced by the enhancers in a variety of tissues. In individuals immune to this form of malaria, the enhancer that is normally expressed in RBC precursors is mutated.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Students have asked these similar questions

The MARCH-1 E3-ubiquitin ligase is expressed in B cells, dendritic cells, and macrophages. The pathway regulated by MARCH-1 is targeted by some pathogens in an immune evasion strategy. In this strategy, the pathogens encode a protein that binds to MARCH-1 and inhibits its function. OOOO a protein that is induced by IL-10 in macrophages and dendritic cells. a protein that induces degradation of MARCH-1. a protein that mimics MARCH-1 and functions similarly.

Aberrant signaling through the Ras-BRaf-MAPK signal transduction pathway drives many cancers. This makes the pathway an attractive drug target, and many small molecules have been developed that target either Ras, BRaf or MAPK. In malignant melanoma, one mutation in particular, where valine 600 of Braf is mutated to a glutamic acid (V600E), is found in the majority of cases. This mutation makes BRaf activation independent of upstream Ras activity. Would a small molecule that targets Ras be effective in a melanoma case driven by Braf V600E? Explain your answer.

Tumor necrosis factor alpha (TNF-α) is an important cytokine used by immune cells to initiate and coordinate inflammatory responses. Inflammation is a key response to cell damage or infection, but can, in some diseases, spiral out of control and become more of a problem than the original cause (COVID-19 lung damage is a relevant example...). TNF-α receptors exist on many cell types. Let’s study the interaction between TNF-α (T) and its receptor (R), to form an activated complex C: T + R ↔ C A macrophage is measured to have ~105 TNF-α receptors on its surface. If the macrophage is immersed in a high concentration of TNF-α molecules (i.e. L0 ≅ L), how will the number of activated receptors change over time? Plot this trend for the case L0 =10 nM, kf=106 M-1 min-1, kr=0.1 min-1. There is constant ligand concentration and an initial condition of C0 = 0. We are given the constants needed to model the number of activated receptors over time and can use the following equation: